Purpose: To exploit the long 3.0T relaxation times and low flow velocity of lymphatic fluid to develop a noninvasive 3.0T lymphangiography sequence and evaluate its relevance in patients with lymphedema. Materials and Methods: A 3.0T turbo-spin-echo (TSE) pulse train with long echo time (TE effective 5 600 msec; shotduration 5 13.2 msec) and TSE-factor (TSE-factor 5 90) was developed and signal evolution simulated. The method was evaluated in healthy adults (n 5 11) and patients with unilateral breast cancer treatment-related lymphedema (BCRL; n 5 25), with a subgroup (n 5 5) of BCRL participants scanned before and after manual lymphatic drainage (MLD) therapy. Maximal lymphatic vessel cross-sectional area, signal-to-noise-ratio (SNR), and results from a five-point categorical scoring system were recorded. Nonparametric tests were applied to evaluate study parameter differences between controls and patients, as well as between affected and contralateral sides in patients (significance criteria: two-sided P < 0.05). Results: Patient volunteers demonstrated larger lymphatic cross-sectional areas in the affected (arm 5 12.9 6 6.3 mm 2 ; torso 5 17.2 6 15.6 mm 2 ) vs. contralateral (arm 5 9.4 6 3.9 mm 2 ; torso 5 9.1 6 4.6 mm 2 ) side; this difference was significant both for the arm (P 5 0.014) and torso (P 5 0.025). Affected (arm: P 5 0.010; torso: P 5 0.016) but not contralateral (arm: P 5 0.42; torso: P 5 0.71) vessel areas were significantly elevated compared with control values. Lymphatic crosssectional areas reduced following MLD on the affected side (pre-MLD: arm 5 8.8 6 1.8 mm 2 ; torso 5 31.4 6 26.0 mm 2
T he lymphatic system is a central component of the body's circulatory system, serving to 1) uptake plasma proteins and ultrafiltrate from blood capillaries; 2) unidirectionally transport this lymphatic fluid through lymphatic vessels (ie, lymphatics) by means of extrinsic contraction of tissue forces and intrinsic pumping of smooth muscle-lined lymphangions; 3) process this fluid in lymphatic nodes; and 4) return the majority of fluid (estimated 3 L per day) back to the blood circulation via the lymphatic ducts and subclavian veins. [1] [2] [3] [4] As such, the lymphatic system is fundamental to maintaining tissue and plasma volume and osmolality homeostasis. Lymphatic vessels range in diameter from several nanometers (lymphatic capillaries) to 2-5 mm (larger collecting lymphatics), transport lymphatic fluid at a comparatively slow velocity (<1 mm/s), and are present systemically. [5] [6] [7] [8] The lymphatic nodes and vessels are the primary route for cancer metastasis, and lymphatic dysfunction has been implicated in a variety of debilitating conditions including lymphedema, hypertension, obesity, infection, and fat disorders. 2, 4, 9, 10 Most recently, lymphatics within the central nervous system (CNS) have been observed, 11, 12 which may have direct relevance for diseases of the CNS with unknown etiology, including multiple sclerosis and Alzheimer's disease. 13 The relevance of improving our understanding of lymphatic functioning has been the topic of multiple recent review articles, 2, 14, 15 yet one barrier to addressing this fully is the lack of imaging methods that can be applied routinely to characterize lymphatic transport. Ex vivo 16 and in vivo 17 magnetic resonance imaging (MRI) work has demonstrated abilities to visualize lymphatic nodes directly at high spatial resolution. Methods proven successful for evaluating tissue health in the brain and other organs are capable of quantifying tissue environment in terms of chemical profile 17 and perfusion 7 and have been applied to the lymphatic system to show discriminatory capacity for lymphatic dysfunction. The relevance of directly visualizing lymphatic vessels using either x-ray fluoroscopy or paramagnetic contrast agents with MR has also been recognized, and there are a growing number of clinical implementations of these methods. 18 While these methods have emerged as important tools for visualizing lymphatic flow, including backflow and alternative routes for understanding individual clinical presentation and treatment, existing lymphangiography methods have limitations. Specifically, these methods require injection of exogenous contrast agents and tracking these agents as they are taken up by lymphatic capillaries and transported by larger lymphatic collectors, which occurs at a low velocity of <1 mm/s. 7, 8 Thus, these methods generally require 45-90 minutes of imaging time, and it remains unclear how exogenous contrast agents influence lymphatic transport. Performing these methods longitudinally or in response to interventions is frequently impractical owing to time, dose restrictions, and reliability of repeated delivery. Recently, relaxation time measurements of water in human lymphatic fluid and tissue have been reported, along with ranges of flow velocities and vessel sizes. 7 This information provides a foundation for developing MRI methods that can directly visualize the lymphatic architecture, and in turn quantify adjustments in lymphatic collector structure in disease. Two elegant studies have utilized estimated lymphatic relaxation times in pelvis and lower extremities to perform lymphangiography of large lymphatic collectors at a field strength of 1.5T, 19, 20 and it has been shown that such contrast correlates with reference-standard methods that require exogenous agents. The purpose of this study was to utilize this recent information to outline a noninvasive 3.0T lymphangiography method, to quantify normative ranges of signal-to-noise ratio (SNR) and imaging characteristics in healthy adults, and to evaluate the ability of this method to detect lymph stasis in patients with breast cancer treatmentrelated lymphedema (BCRL). A secondary aim was to evaluate whether lymph stasis decreased following a single session of manual lymphatic drainage (MLD) therapy. For this supplemental aim we evaluated the cohort of patients (n 5 5; age range 5 64-81 years; mean age 5 70 years) who were imaged before and immediately after MLD therapy. Note that the MLD component of the study was intended only to evaluate whether lymphatic collector contrast changed in an expected manner before and after MLD. Information regarding lymphedema stage, time since lymph node dissection, and lymphedema location were determined by a Lymphology Association of North America (LANA)-certified physical therapist (P.M.C.D.).
Materials and Methods

Volunteer Demographics
Acquisition
All volunteers were scanned at 3.0T (Philips Healthcare, Best, The Netherlands) using body coil radiofrequency transmission and a 16-channel torso coil for reception. First structural imaging, consisting of diffusion-weighted imaging with background suppression (DWIBS), 21 T 2 -weighted, and T 1 -weighted imaging of the axillary nodes was performed to identify axillary lymphatic node locations using previously reported imaging parameters. 17 
MLD Intervention
In a subgroup of volunteers, the imaging protocol was repeated immediately following a 50-minute session of MLD that was performed by the same certified lymphedema physical therapist. The MLD session consisted of stimulating the bilateral supraclavicular fossae, cervical lymphatic nodes, shoulder collectors, and axillary lymphatic nodes, along with stimulating anterior and posterior axillo-axillary pathways, ipsilateral inguinal lymphatic nodes, and axillo-inguinal pathway, deep abdominals, involved quadrant, and arm applying stretch to the tissues proximal to distal toward the direction of intended lymphatic flow with temporary redirection towards uninvolved orthogonal truncal quadrants and involved posterior shoulder.
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Analysis
The analysis was divided into a quantitative assessment of fractional lymphatic signal, SNR, and maximal lymphatic vessel crosssectional area as well as a categorical scoring of the lymphatic angiography sequence by two raters. All quantitative measurements were recorded from orthogonal magnitude image reconstructions of the lymphangiography scan, and the five-point categorical scoring was performed on a 3D maximum-intensity-projection (MIP) of the lymphangiography scan.
LYMPHATIC SIGNAL. Fractional lymphatic signal (S/S 0 ) was calculated by choosing the largest discernable lymphatic vessel on the lymphangiography scan, separately in the arm and torso. The signal was normalized by the equilibrium signal (S 0 ), which was calculated from the measured CSF signal (discernable from the thoracic segment of the spinal cord) and scaled to equilibrium using an identical equation presented in the literature 23 and using the previously published water density of CSF of 1 mL water/mL CSF, 24 along with TR 5 3000 msec, T 1,CSF 5 4300 msec, 25 TE 5 600 msec, and T 2,CSF 5 1442 msec. 26 The evolution of the signal is also shown for these parameters in Fig. 1B .
LYMPHATIC FLUID SNR. In the same regions as described above, the lymphatic signal was normalized by a noise measurement taken from an identical volume in all subjects and SNR was recorded.
LYMPHATIC VESSEL SIZE. In the same regions, the crosssectional areas of the lymphatic vessels were recorded. These measurements were taken at the maximum discernable diameter of the lymphatic vessels in the axial imaging plane in both control and patient volunteers, noting that larger diameters may be representative of lymph stasis or vessel impairment. This procedure is analogous to procedures for grading stenosis degree on blood angiography images. Care was taken to avoid extravascular, (subcutaneous) edema, pleural effusion, glenohumeral joint effusion, fluid within the long head biceps tendon sheath, and other fluid not localized to lymphatics. Lymphatic vessels had to be continuous through multiple slices in orthogonal reconstructions; the images were resliced perpendicular to the lymphatic vessel on the sagittal and coronal representations and drawn on the axial image.
RADIOLOGICAL SCORING. Two raters also evaluated a 3D MIP of the lymphangiography scan using the scoring system proposed in Table 1 . The scoring system is intended to reflect contrast consistent with increasing levels of lymphatic stasis and vessel tortuosity, as hypothesized responses to mechanical insufficiency induced by lymph node removal. The raters consisted of two clinical readers, both faculty radiologists at our institution (K.G.H. and A.A.D.), one with subspecialty training in musculoskeletal radiology and one with subspecialty training in breast radiology. Rating was performed independently and a consensus score was determined by agreement when individual scores were discordant.
Statistical Considerations
The objectives of this study were to quantify the normative ranges of lymphatic fluid signal and SNR, lymphatic vessel diameter, and radiological scoring in patients with BCRL and age-matched female controls, as well as to evaluate whether these parameters were discriminatory for lymphedema. A secondary objective was to physically modulate the distribution of lymphatic fluid in the upper extremities and quadrants using MLD therapy and evaluate whether lymphangiography contrast decreased in the affected arm and torso of patients immediately following the intervention. Descriptive statistics, including means, standard deviations, and ranges for continuous parameters were calculated. Investigations for outliers (2.5 standard deviations from the mean) were made. To test the difference in study parameters between controls and patients with BCRL, the Wilcoxon rank-sum test was applied. To evaluate differences in study parameters before and after MLD, as well as between left and right sides, the matched Wilcoxon signed-rank test was applied. In all cases, a corrected P < 0.05 was required for significance. Due to the small sample size in the MLD component of the study, an effect size was also calculated (Cohen's d). Cohen's kappa was calculated to evaluate interrater agreement in the scoring system with agreement classifications defined using previously reported agreement criteria 27 
Results
The proposed lymphangiography pulse sequence along with simulated signal is shown in Fig. 1A ,B. The middle of the echo train occurs when the lymphatic fluid signal is 16% of the equilibrium signal S 0 and blood and muscle signal are null. The measured SNR was 13.4 6 5.6 and 10.4 6 4.2 in the control arm and torso, respectively, and did not differ significantly between left and right (P 5 0.70) or between arm and torso (P 5 0.067). The measured fractional lymphatic signal (S/S 0 ) was 9.8 6 4.4%. Structural imaging in a control volunteer is shown in Fig. 1C -G, and depicts the location of axillary lymphatic nodes over which the lymphangiography scan was planned, along with a reconstructed MIP of the lymphangiography scan. Note that since lymphatic node T 1 and T 2 are substantially lower than lymphatic fluid T 1 and T 2 , the lymphatic nodes are not clearly visible in the lymphangiography sequence. For completeness, results from the high spatial resolution structural imaging FIGURE 1: (A) Relevant components of the proposed lymphangiography sequence, which consists of spectral presaturation with inversion recovery (SPIR) and spatially selective presaturation pulses for fat and inflow suppression, respectively. Preparation is followed by a long turbo-spin-echo (TSE) readout (TSE-factor 5 90; echo spacing 5 13.2 msec; effective echo time 5 600 msec). (B) These parameters lead to a fast decay of blood and muscle signal over the readout, yet a slower decay of lymphatic and CSF magnetization due to longer T 2 and lower velocity of these species. For a health control volunteer, (C) structural imaging of lymphatics are displayed as the maximum intensity projection (MIP) from diffusion-weighted-imaging-with-background suppression (DWIBS), and (D) the lymphangiography sequence, showing the thoracic duct (large central white arrow) and convergence of apparent lymphatic vessels near the axillary lymph nodes (white arrows). Note that since lymphatic node T 1 and T 2 are substantially lower than lymphatic fluid T 1 and T 2 , the lymphatic nodes are not clearly visible in the lymphangiography sequence. (E-G) High spatial resolution structural imaging at the site of an axillary lymphatic node (white arrow).
are also shown, highlighting the approximate location and depth of the axillary lymphatic nodes. In control volunteers, lymphatic vessel cross-sectional area measurements were not found to be significantly different when considering the arm (P 5 0.76; left 5 8. ; torso 5 9.1 6 4.6 mm 2 ) side; this difference was significant both for the arm (P 5 0.014) and torso (P 5 0.025). Furthermore, when compared with control values, the patients' affected (arm: P 5 0.010; torso: P 5 0.016) values were significantly elevated, whereas Table 2 , and a lymphangiography scan from a representative patient is shown in Fig. 3 . Next, data were considered using the categorical scoring system rather than the quantitative cross-sectional area measurements. Moderate agreement was found between the two independent raters (Cohen's kappa 5 0.50; confidence interval 5 0.35-0.64) with an agreement due to true concordance (observed agreement -random agreement) of 0.36. The lymphatic duct was visible in 100% of control volunteers and 88% of patient volunteers. Lymphangiography scans were considered of acceptable quality in 100% of controls and 92% (23/25) of patients with BCRL. Unacceptable quality in the two cases was attributable to an artifact from sternal wires in one case and a large motion artifact in the other. Consensus scores from both raters are summarized in Table 2 . Scores did not differ significantly between left and right sides in control volunteers (P 5 1.0; left 5 1.9 6 0.8; right 5 1.9 6 0.8); the scores also did not differ significantly between affected and contralateral sides considering all BCRL patient volunteers (P 5 0.82; affected 5 2.1 6 1.3; contralateral 5 2.2 6 1.3). However, when only patients with symptomatic Stages 1-2 BCRL were considered, the categorical score was higher (P 5 0.048) in the affected side (score 5 2.7 6 1.5) compared to control volunteer scores, but not compared to contralateral scores in the same patients (P 5 0.22). These findings are consistent with the categorical scoring system having moderate agreement between independent raters, but having potential specificity for distinguishing healthy from diseased conditions primarily in symptomatic patients.
Finally, in the subgroup of patients scanned before and after MLD, maximal lymphatic cross-sectional area was observed to reduce on the affected side (pre-MLD: arm 5 8. ). This change was significant in the torso region (P 5 0.036) and just beyond criteria for significance in the arm region (P 5 0.054). No change was observed before vs. after MLD in the contralateral regions (pre-MLD: arm 5 10. ) for either arm (P 5 0.97) or torso (P 5 0.71). Before MLD, the categorical scores were 4.2 6 0.4 and 2.0 6 0.7 on the affected and contralateral side, respectively. After MLD, the scores were 3.6 6 0.9 and 1.6 6 0.5 on the affected and contralateral side, respectively. These changes did not meet statistical criteria for significance on either the affected (P 5 0.37) or contralateral (P 5 0.18) sides; however the effect sizes were large on both the affected (Cohen's d 5 0.81) and contralateral (Cohen's d 5 0.63) side. An example of a patient scanned before and immediately after MLD is shown in Fig. 4 . Figure 5 summarizes the group-level results.
Discussion
We utilized recently measured 3.0T MRI relaxation times of lymphatic fluid and known ranges of lymphatic and blood flow velocities to propose a noninvasive 3.0T lymphangiography pulse sequence. The sensitivity of the sequence to lymphatic fluid, relative to blood, was first investigated through simulations, after which normative ranges of SNR were calculated in healthy adult female participants. Maximal lymphatic collector cross-sectional area was calculated in healthy participants and patients with known lymphatic compromise, as a potential quantitative measure of lymph stasis. A categorical radiologic scoring system was also devised based on lymphangiograms from patients with BCRL. The primary findings are that maximal lymphatic cross-sectional area was elevated on the affected side of patients with BCRL relative to the contralateral side and control values. The five-point categorical scoring system provided elevated scores on the affected side of advanced stage patients only, indicating that the scoring system (categorical variable) is less sensitive to lateralizing BCRL pathology than the continuous variable of lymphatic vessel measurements.
A concern while developing this protocol was that blood and lymphatic vessels appear very similar in MIP reconstructions, and these vessels are often in close proximity, such that distinguishing between the two can be difficult. In anticipation of this, we implemented several procedures for ensuring that blood-water signal was suppressed. First, we utilized a long echo time sequence (TE effective 5 600 msec; TE equivalent 5 491 msec). While 3.0T lymphatic T 2 is 610 msec, 7 3.0T venous and arterial blood-water T 2 are less than 50 msec and 150 msec, respectively, including microvessels with a hematocrit < 0.30. 28 Therefore, residual blood-water signal is 1% for the majority of the readout. Additionally, we incorporated a long TSE pulse train (TSEfactor 5 90; shot duration 5 1187 msec), which serves to inefficiently refocus fast-flowing spins, as is the case for blood-water. Finally, the possibility of inflow of fresh blood-water was a concern, and to reduce this we implemented broad spatially selective excitation pulses with dephasing gradients above and below the imaging volume. We calculated the signal in the hypothesized lymphatic vessels and found that the signal was similar to the estimated signal from the Bloch equation simulations for lymphatic fluid; however, slightly reduced potentially due to partial volume effects at our spatial resolution. The simulated blood-water signal was less than 1% by the center of the echo train.
Lymphatic vessels are generally reported to be 2-5 mm in diameter (for large vessels such as the thoracic trunk) ranging down to several nanometers for smaller vessels. 5 Our spatial resolution (in-plane 5 1.39 3 1.39 mm 2 ) allowed for quantification of only larger lymphatic collectors (minimal cross-sectional diameter of 1-2 mm). In healthy subjects, we found the largest lymphatic arm and torso collectors to have a cross-sectional area of 8-9 mm 2 , with corresponding diameter of 3-3.4 mm. This is approximately consistent with expected sizes for larger lymphatic vessels in these regions, which have been suggested to fluctuate in diameter from 2-4 mm for a lymphatic fluid flow of 1-3 ml/min and pressure of 1.5 mmHg. 29 The refocusing pulse train used in this study utilized a constant refocusing angle of 1108 and startup dummy echoes in which no data were acquired to reduce signal instability for early refocusing pulses. This strategy was implemented to reduce the specific absorption ratio (SAR) while still maintaining adequate lymphatic signal across the TSE pulse train. We additionally investigated variable FIGURE 5: Summary of primary study findings. (A) Maximal lymphatic cross-sectional area did not differ significantly between left and right sides in controls, but was significantly elevated in the affected relative to contralateral side of patients. This was found both for arm and torso vessels and for both symptomatic (Stages 1-2) and subclinical patients. (B) The categorical scoring system was less sensitive to lateralizing disease. Neither left vs. right scores in controls, nor affected vs. contralateral scores in all patients, were significantly different. When only symptomatic patients were considered, the scores in the affected side were significantly elevated relative to control scores. (C) In the subgroup of patients scanned before and after MLD, maximal lymphatic cross-sectional area was observed to reduce on the affected side only; this change was significant in the torso region and just beyond significance criteria in the arm region. (D) The categorical score changes pre-vs. post-MLD were not significant; however, the effect sizes for the reductions were large on both the affected (Cohen's d 5 0.81) and contralateral (Cohen's d 5 0.63) side. *Two-sided P < 0.05; #One-sided P < 0.05. Values summarized are mean 6 one standard error of the mean. Standard deviations are summarized as well in Table 2. refocusing angles (eg, combinations of refocusing sweep ranges from 10-1808) as have been summarized in the literature for separate applications. 23, 30 While it is possible to slightly reduce the decay of the lymphatic signal across the readout with different sweep parameters, this comes at the cost of also increasing the residual blood-water signal. However, future studies that experimentally investigate the effect of the refocusing pulse train properties on blood and lymphatic fluid signal could be important for improving SNR and narrowing the lymphatic fluid point spread function. Additional suppression of blood-water spin isochromats could be achieved using principles of velocity-induced phase suppression and delay alternating with nutation for tailored excitation (DANTE) modules, which have been successful in suppressing both slow blood flow near the perimeter of vessels as well as slow CSF flow in intracranial vessel wall imaging applications. 25, 35 have flow velocities that are low, and relaxation times that are long, compared to blood. 28, 36 Therefore, CSF signal is also expected to appear bright in the proposed lymphagiography sequence, as demonstrated by the simulations presented here and the case examples. Since CSF is localized to the spinal cord, this was not a major concern, and CSF regions can easily be cropped out of orthogonal MIP representations, as is frequently performed for intracranial blood time-of-flight MR angiography reconstructions. Other applications of the lymphangiography sequence to cervical lymphatic vessels or nodes, or to applications in the central nervous system, may benefit from different reconstruction and acquisition parameters that desensitize the sequence to CSF. Noninvasive lymphangiography techniques could have broad relevance, both in research studies for investigating onset and mechanisms of lymphatic compromise as well as in a clinical setting as part of screening protocols. In the research setting, lymph stasis and altered vessel structure are well-known effects of lymphatic dysfunction, especially following breast cancer, where secondary lymphedema occurs in 30% of breast cancer survivors experiencing lymph node dissection and radiation therapy. 37 Lower extremity lymphedema has a conservative reported prevalence of 10-36% in patients undergoing gynecological or prostate cancer therapies including sentinel node biopsy, and 12-64% in patients undergoing aggressive dissection for melanoma cancer. 38, 39 Therapy management, including MLD as a component of complete decompression therapy, has generally not been optimized. Controversy remains as to how MLD impacts lymphatic functioning and, if so, then for what duration and for which individual. Noninvasive biomarkers of lymphatic flow and lymphatic vessel cross-sectional area could therefore serve as endpoints in longitudinal trials of therapy optimization, and in particular enable detection of intact pathways for clearance in a patient-specific manner. The radiological five-point scoring system proposed here was based on expected changes in lymphatic fluid accumulation as a function of increasing lymphedema stage, and therefore is based on physiological expectations rather than rigorous evaluation of correspondence between imaging findings and prognosis or diagnosis. The results are consistent with the lymphangiography sequence detecting quantitative changes in maximal lymphatic vessel area immediately after MLD; however, assessing change in lymph stasis is less clear when only using the categorical grading system. It was observed that while the extent of contrast consistent with lymph stasis reduced following MLD, as evidenced by the cross-sectional area scores, the overall category of the image did not shift in general. Otherwise stated, a patient may exhibit the same general pattern of contrast for the same score, just the extent of pattern may be lower. The current study was powered to demonstrate expected differences in lymphangiography contrast between patient and control volunteers; however, future work in a larger cohort would benefit from rigorously evaluating the sensitivity of this scoring system and refining the categories where appropriate, and finally by internally validating the calibration and discrimination using the bootstrap to estimate the model's likely performance on a new sample of subjects from the same patient stream.
The noncontrast lymphangiography method was shown to provide visualization of lymphatic vessel dysfunction consistent with lymph stasis and/or lymphatic structural impairment in patients with unilateral BCRL. These findings warrant further investigation of the varying degrees of lymphatic vessel dysfunction and the relationship to condition severity as well as response to therapies intended to optimize and/or restore lymphatic pumping. In the given patient cohort, the mechanism causing lymphatic impairment is thought to be a condition of impaired pumping brought on by a mechanical insufficiency after axillary lymphatic node removal. MR lymphangiography may have the potential to evaluate the degree of lymphatic fluid reflux and lymphatic network response to the known insults from cancer therapies, as well as investigate structure dysfunction in cases of primary lymphedema with unknown causes. Understanding the degree and involvement of lymphatic dysfunction would likely inform the most effective prevention and management therapies for lymphedema and provide a more sensitive means of precision medicine through periodic surveillance of an individual's lymphatics. For example, with our noted patient example pre-and post-MLD session, her post-MLD lymphangiography indicates a specific need for future MLD sessions to focus attention on rerouting the remaining congestion along the upper lateral chest wall to the ipsilateral lower quadrant following her visualized lymphatic collector pathways. Additionally, there is also an opportunity for lymphangiography to inform a patient's individual risk of developing secondary lymphedema through pretreatment evaluation of their intact and otherwise assumed healthy lymphatic system, which may provide researchers and clinicians with a new prognostic measure indicative of higher predisposition for secondary lymphedema given premorbid status.
The findings should also be considered in the context of several limitations. First, the sample size utilized (n 5 36), including 11 control and 25 BCRL patients, is too small to allow for clinical questions regarding lymph stasis to be rigorously addressed, and rather was intended to investigate the ability of the proposed method to identify lymph stasis only in the first instance. Future work with a larger cohort spanning more anatomical regions and representing more primary and secondary lymphedema stages is warranted to investigate clinically relevant questions. Second, the spatial resolution employed here was not sufficient to allow for lymphatic collectors with a cross-sectional area less than 2 mm 2 to be depicted, and therefore this method is primarily sensitive to lymphatic stasis present in patients with lymphedema where vessels appear engorged. Future work should focus on improving the spatial resolution, which could be accomplished by lowering the TSE shot number and reducing the FOV to focus on a more confined region of interest. It is likely that the measured lymphatic signal was underestimated slightly relative to simulation due to partial volume effects between the perimeter of the vessel and surrounding tissues. Third, no independent reference standard was utilized in this study. The standard for lymphangiography remains x-ray fluoroscopy, and coregistering such lymphangiograms, which are necessarily acquired in separate scan sessions and locations, is not straightforward. Future work that utilizes Gd-based lymphangiography, which can be performed in 60 minutes and in the same scan session as the proposed noninvasive lymphangiography scan, would be a logical extension to better validate this sequence and is being pursued in ongoing investigations.
In conclusion, we demonstrate for the first time abilities to perform 3.0T lymphangiography of the upper body noninvasively using turbo-spin-echo MR pulse sequences. Contrast consistent with lateralizing disease was observed in patients with known secondary lymphedema from breast cancer treatment-related lymphedema, which also adjusted in an expected manner following manipulation of lymph stasis through manual lymphatic drainage therapy. These findings suggest that MR has potential to evaluate lymphatic functioning and lymphedema treatment response, and may have relevance for informing personalized lymphedema risk and precision-treatment.
